Paper Details

  1. Home
  2. Paper Details

Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices.

Author: B vd LippeB, BellH, BjøroK, ChristophersenP, EvensenS, FrølandS S, KrarupH, LaursenA, MaelandA, RanekL

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The higher dose group of recombinant interferon-alpha-2b for 48 weeks had a significantly higher rate of sustained alanine aminotransferase (ALAT) response (45% versus 19%) and a significantly better chance of becoming HCV RNA-negative during therapy (47% versus 23%).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Recombinant interferon remains the cornerstone of treatment of chronic hepatitis C virus (HCV) infection. Still, evaluation of treatment on the basis of response indicators and long-term effect of the treatment raises several questions. METHODS: Seventy-four patients with chronic HCV in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/00365529509101617

データ提供：米国国立医学図書館（NLM）

Finding the Right Dose for Hepatitis C Treatment

Hepatitis C is a serious liver infection that can lead to long-term health complications, including cirrhosis and liver cancer. Researchers in the field of infectious disease are constantly searching for effective treatments for hepatitis C, aiming to improve patient outcomes and minimize the risk of complications. This study investigates the effectiveness of two different dose regimens of recombinant interferon-alpha-2b, a medication used to treat hepatitis C.

The Impact of Dose on Hepatitis C Treatment

This study found that a higher maintenance dose of recombinant interferon-alpha-2b resulted in a significantly higher rate of sustained alanine aminotransferase (ALAT) response, a measure of liver function improvement. The study also found that the higher dose group had a significantly better chance of becoming HCV RNA-negative, indicating successful viral suppression. Furthermore, the higher dose group showed more improvement in liver biopsy findings, suggesting better overall liver health. These findings suggest that a higher maintenance dose of interferon-alpha-2b may be more effective in achieving sustained viral suppression and improving liver health in patients with hepatitis C.

Implications for Hepatitis C Treatment

These findings have important implications for hepatitis C treatment, highlighting the potential benefits of a higher dose regimen of interferon-alpha-2b for certain patients. The study underscores the need for careful consideration of individual patient factors, including their liver function and viral load, when determining the optimal dose of this medication. This research provides valuable insights into the complex relationship between dose and treatment outcomes, guiding clinicians in selecting the best treatment approach for each patient.

Dr.Camel's Conclusion

This study is like a seasoned camel guide, navigating the intricate landscape of hepatitis C treatment. It reveals that the right dose of interferon-alpha-2b can make all the difference in achieving a successful treatment outcome, highlighting the importance of individualizing treatment to optimize patient care.

Date :
  1. Date Completed 1996-03-11
  2. Date Revised 2019-08-14
Further Info :

Pubmed ID

8578174

DOI: Digital Object Identifier

10.3109/00365529509101617

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.